CRIS Current Research Information System

MARTELLO, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.588
NA - Nord America 2.480
EU - Europa 1.843
AF - Africa 223
SA - Sud America 127
OC - Oceania 2
Totale 7.263
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.447
CN - Cina 730
SG - Singapore 691
VN - Vietnam 636
IT - Italia 588
GB - Regno Unito 287
DE - Germania 231
HK - Hong Kong 194
SE - Svezia 184
IN - India 135
NL - Olanda 119
KR - Corea 107
BR - Brasile 93
CI - Costa d'Avorio 86
RU - Federazione Russa 86
IE - Irlanda 70
FR - Francia 68
SC - Seychelles 42
TG - Togo 41
FI - Finlandia 40
ZA - Sudafrica 27
BG - Bulgaria 26
CH - Svizzera 26
AT - Austria 24
NG - Nigeria 23
UA - Ucraina 23
JP - Giappone 20
EE - Estonia 19
CA - Canada 18
AR - Argentina 17
ID - Indonesia 17
BE - Belgio 13
PL - Polonia 13
JO - Giordania 11
ES - Italia 10
IR - Iran 10
MX - Messico 10
TR - Turchia 8
PH - Filippine 7
EC - Ecuador 6
RO - Romania 5
BD - Bangladesh 4
CO - Colombia 4
HR - Croazia 3
IQ - Iraq 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
CY - Cipro 2
CZ - Repubblica Ceca 2
IL - Israele 2
LT - Lituania 2
RS - Serbia 2
SA - Arabia Saudita 2
SV - El Salvador 2
UZ - Uzbekistan 2
AO - Angola 1
AU - Australia 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GT - Guatemala 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
UY - Uruguay 1
VE - Venezuela 1
Totale 7.263
Salva come PNG Salva come JPEG
Città #
Singapore 443
Ashburn 328
Chandler 275
Southend 243
Hefei 237
Ho Chi Minh City 196
Hong Kong 194
Dallas 193
Fairfield 188
Bologna 156
Hanoi 130
Ann Arbor 121
Seoul 107
Beijing 92
Abidjan 86
Houston 79
Woodbridge 78
Wilmington 77
Dublin 70
Seattle 69
Cambridge 67
Princeton 66
New York 53
Milan 50
Boardman 47
Los Angeles 47
Santa Clara 47
Lomé 41
Dong Ket 38
Hyderabad 38
Munich 36
Bremen 31
Nanjing 31
Helsinki 29
Fabriano 27
Sofia 26
Haiphong 25
Westminster 23
Bengaluru 22
Turin 22
Abeokuta 20
Berlin 20
Buffalo 20
Padova 20
Salsomaggiore Terme 20
Tokyo 20
Redmond 18
Vienna 18
Amsterdam 17
Frankfurt am Main 17
Bern 16
Rome 16
Ha Long 15
Redondo Beach 15
Medford 14
Shenyang 14
São Paulo 14
Biên Hòa 13
Brussels 13
Nuremberg 12
Redwood City 12
Saint Petersburg 12
Toronto 12
Amman 11
Falkenstein 11
Florence 11
Jakarta 11
Jinan 11
Ninh Bình 10
Quận Bình Thạnh 10
Quận Một 10
Mondolfo 9
Thái Nguyên 9
Warsaw 9
Wuhan 9
Guangzhou 8
Lappeenranta 8
Nanchang 8
Orlando 8
Tianjin 8
Zhengzhou 8
Brooklyn 7
Changsha 7
Des Moines 7
Hebei 7
Naples 7
Shanghai 7
Tongling 7
Yubileyny 7
Bắc Ninh 6
Coimbatore 6
Da Nang 6
Dearborn 6
Falls Church 6
Hangzhou 6
Kuban 6
London 6
Modena 6
Monmouth Junction 6
Norwalk 6
Totale 4.787
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 663
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 228
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 198
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 186
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 183
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 181
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 175
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 173
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 173
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 169
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 168
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 168
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 168
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 166
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 161
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 158
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 157
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 151
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 148
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 148
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 148
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 146
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 146
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 137
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 132
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 131
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 129
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 128
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 126
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 124
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 122
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 121
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 120
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 118
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 117
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 115
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 110
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 108
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 107
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 99
null 98
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 96
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 93
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts 85
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 77
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 69
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 60
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 50
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 41
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 21
null 17
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 13
Totale 7.421
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021262 0 0 0 0 0 27 19 33 62 17 18 86
2021/2022794 73 41 37 62 62 41 27 50 40 99 120 142
2022/20231.073 96 140 47 170 81 80 29 57 157 48 84 84
2023/2024486 39 46 43 39 31 97 26 88 14 19 24 20
2024/20251.363 98 132 112 110 121 61 111 57 30 156 126 249
2025/20262.439 356 964 354 322 372 71 0 0 0 0 0 0
Totale 7.421